• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

What is the Price of the Potential for a Meaningful Recovery following Intracerebral Hemorrhage?
In this issue of the Journal of Stroke and Cerebrovascular Diseases, Vardanyan and colleagues report on the cost-utility of minimally invasive surgery (MIS) with thrombolysis for spontaneous intracerebral hemorrhage (ICH) from the perspective of the United Kingdom (UK) National Health Service (NHS)1 using data from the Minimally Invasive Surgery Plus Alteplase in Intracerebral Hemorrhage Evacuation (MISTIE III) trial2 and the UK Sentinel Stroke National Audit Programme (SSNAP).3 The economic evaluation revealed that the incremental cost-effectiveness ratio for MIS with thrombolysis fell significantly above the UK's Nationa...
Source: Journal of Stroke and Cerebrovascular Diseases - July 27, 2021 Category: Neurology Authors: Lourdes R. Carhuapoma, Avni Kapadia, Henry A. Glick, Daniel F. Hanley Source Type: research

NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective
Abstract The National Institute for Health and Care Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical and cost-effectiveness of alteplase for the prevention of strokes within a 0–4.5 h window. The comparator was standard medical and supportive management that does not include alteplase. This paper provides a description of the company submission, the Evidence Review Group (ERG) review and NICE's subsequent decisions. Clinical effectiveness evidence for alteplase was derived from 5 trials. For the 3–4.5 h treatment window, alteplase did not...
Source: PharmacoEconomics - November 26, 2014 Category: Health Management Source Type: research